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Application of nanoscale materials (NMs) displays a rapidly increasing trend in electronics, optics, chemical catalysis,
biotechnology, and medicine due to versatile nature of NMs and easily adjustable physical, physicochemical, and chemical
properties. However, the increasing abundance of NMs also poses significant new and emerging health and environmental risks.
Despite growing efforts, understanding toxicity of NMs does not seem to cope with the demand, because NMs usually act
entirely different from those of conventional small molecule drugs. Currently, large-scale application of available safety assessment
protocols, as well as their furthering through case-by-case practice, is advisable.We define a standard work-scheme for nanotoxicity
evaluation of NMs, comprising thorough characterization of structural, physical, physicochemical, and chemical traits, followed
by measuring biodistribution in live tissue and blood combined with investigation of organ-specific effects especially regarding the
function of the brain and the liver. We propose a range of biochemical, cellular, and immunological processes to be explored in
order to provide information on the early effects of NMs on some basic physiological functions and chemical defense mechanisms.
Together, these contributions give an overview with important implications for the understanding of many aspects of nanotoxicity.
1. Safety Control of Nanoscale Materials
Necessitates Understanding of the Currently
Unexplored Potential Toxic Effects
Generally characterized by 1–100 nm range in at least two
dimensions [1], nanoscale materials (NMs) keep being pro-
gressively applied in many important fields including elec-
tronics, optics, chemical catalysis, solar fuel, agriculture,
biotechnology, and medicine (e.g., see [2–6]). Built on and
confirming earlier documents, SCENIHR emphasized that
methodologies to assess exposure to manufactured NMs and
the identification of potential hazards require further devel-
opment. For lack of a general approach, SCENIHRmaintains
to perform risk assessment case by case for each NM in
accordance with the practice of the Nanotechnology Char-
acterization Laboratory at the National Cancer Institute ( [7]
http://ncl.cancer.gov/assay cascade.asp). The effects of NMs
in biological systems are by now recognized to be entirely
different from those of conventional chemicals or biological
agents due primarily to their microscopic size [1]. Despite
the major efforts worldwide, the scientific basis underlying
these unprecedented effects allowing proper safety control of
NMs does not seem to cope with the demand. In order to
meet the requirements of a knowledge-based control of the
environmental, especially the health-related effects of NMs,
a new and synergistic strategy for research groups working
in the areas of NM science and biology is much needed. The
European Commission’s Framework Programmes (FPs) sup-
port and encourage research and development in nanotech-
nology, especially in the fields related to environment, health,
and safety issues (nanoEHS). Key projects identified in this
2 BioMed Research International
regard include knowledge transfer, standardisation, regula-
tion, guidance, and public engagement, as well as the role
of professional bodies. Among many projects dealing with
nanosafety, some of them are focusing on the measurement
difficulties associated with NMs like the NanoChOp project
(http://nanochop.lgcgroup.com) founded by the European
Association of National Metrology Institutes (EURAMET),
while others aim at the stakeholder driven intelligent testing
strategy in nanoEHS [8]. Although several projects have
already been funded to investigate the potential nanoEHS
issues of NMs within successive FPs, a knowledge-based
understanding also supported by this BMRI thematic issue
on nanotoxicity may significantly improve to identify and
address the specific research aspects underlying biomedical
applications of NMs.
2. Promoting Awareness on NMs through
Novel Approaches and Techniques
We are well aware that understanding NM toxicity needs
more comprehensive, complex, and novel multi- and inter-
disciplinary approaches [9–23]. These are driven in many
cases by furthering imaging techniques throughmore specific
labeling and detection of the cellular fate ofNMs as illustrated
by (i) in vitro/in vivo fluorescence ([22, 24]; Figure 1),
synchrotron radiation-based (SR) Fourier transform infrared
spectroscopy (FTIR) or X-ray fluorescence microscopy [25],
or single photon emission computed tomography combined
with X-ray computed tomography (SPECT-CT) imaging to
study NM biodistribution at organ levels (Figure 2); (ii)
small-angle X-ray (SAXS; Figure 3) or neutron scattering
[26–28], freeze-fracture combined transmission electron
microscopy (FF-TEM) and sum-frequency generation (SFG)
vibrational spectroscopy for determination of structure or
membrane interactions of NMs [13], and in situ high-
resolution TEM [29]; (iii) application of new sets of method-
ologies built on basic instrumentation and related expertise
in combination with NM surface modifications and toxicity
assaying. For example, alterations of dendrimers combined
with high-resolution NMR, capillary electrophoresis, elec-
trophysiology and computer-assistedmodeling of membrane
interactions [11] or the adjustment of chitosan-based NM
combined with Fourier transform infrared (FTIR) spec-
troscopy, transmission electron microscopy (TEM), atomic
force microscopy (AFM), flow cytometry and near-infrared
(NIR) fluorescence spectroscopy in vivo [22] may also be
critical to rigorously characterize NM traits and relate them
to nanotoxicity parameters to be assessed.
3. Emerging Consensus
The papers referred to below, a mixture of reviews and
research articles, are divided into three parts in line of emerg-
ing consensus.The first section conveys information on prob-
ably the best-known and most intensively studied biosimilar
NMs applied in biotechnology and medicine such as lipo-
somes, chitosan, and poly(lactic-co-glycolic acid) (PLGA)
nanoparticles. These biocompatible and biodegradable NMs
represent wide potential use in delivering a large variety of
drugs and therapeutics including small molecules, herbal
medicines, genes, proteins, miRNAs, and oligonucleotides
([30, 31] and references cited; [9, 14, 22, 25, 32–34]). The
focus of the second section is on the possibility to conclude
on trait-nanotoxicity relationships. Among polymeric NMs,
that can encapsulate drug molecules and can be conjugated
to targeting agents, dendrimers [11, 19, 31, 35–38] are the
preferred test materials, due to their versatile surface func-
tions allowing a wide variety of chemical modifications of
properties. By reflecting preclinical studies using NMs for
the delivery of therapeutics designed for neuroinflammation
and neurodegeneration such as Alzheimer’s and Parkinson’s
diseases, multiple sclerosis or amyotrophic lateral sclerosis
(ALS), cerebral palsy, ischemia/stroke, traumatic brain injury,
and epilepsy ([31] and references cited), the third section
concerns the growing realization of the unique biodistribu-
tion of NMs. It necessitates the development of new model
systems providing parameters predictive for NM action in
various disorders and pathophysiological conditions. In the
conclusion section we propose to set a “preclinical” work-
scheme used for single nanotoxicity assessment of each NM
considered in biomedical applications.
4. Furthering Evidence on Biocompatible and
Biodegradable poly(lactic-co-glycolic acid)
(PLGA), Liposome, and Chitosan NMs
Amongst first choice biodegradable and biocompatible poly-
mers, PLGAhas already been approved byUnited States Food
and Drug Administration and European Medicine Agency
for parenteral administration. PLGA serves as an effective
NM for the delivery of therapeutics enabling organ, tissue, or
cell-specific targeting [25, 30, 33, 39]. PLGA-based nanovec-
tor platform adaptable to formulate hydrophilic or hydropho-
bic small molecules or macromolecules gives rise to many
possibilities including protection of drugs from degradation,
sustained release, and easy surface-property modification
enabling versatile, tunable, and more specific applications.
For further understanding of specific characteristics utilized
by PLGA-basedNMs, we refer to a recent and comprehensive
review [33]. By collecting a vast body of evidence, Danhier et
al. argue for PLGA as the proper choice for planning drug
delivery systems in various biotechnological and medical
applications (vaccination, cancer, inflammation, etc.).
Together with other forms of self-organizing lipid-
systems, liposomes (vesicles) have widely believed to provide
the less harmful substrate for biomedical applications [5, 9,
31]. This concept derives from the fact that liposomes and
the cell membrane have similar lipid bilayers. Moreover, the
existence of natural intra- and extracellular vesicles provides
the reality and perspective of lipid nanocarriers ([23] and
references cited). The special structure of the liposomes,
namely, the aqueous core surrounded by the phospholipid
bilayer, enables the incorporation of both hydrophilic and
hydrophobic drugs. The tailoring of liposomes by varying
their lipid components makes the efficient encapsulation
of drugs and labeling molecules (radiopharmaceutics, dye
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Figure 1: In vitro cellular uptake of fluorophore dye-conjugated anionic (G4.5-COONa) and cationic (G5-NH
2
) polyamidoamine (PAMAM)
dendrimers. Confocal laser microscope images were taken after 1 h incubation of hepatocytes (a and c) and Kupffer cells (b) with PAMAM
dendrimers. The anionic G4.5-COONa dendrimer was conjugated with 5(6)-TAMRA cadaverine HCl salt while the cationic G5-NH
2
dendrimer was coupled with 5(6)-TAMRA NHS ester as fluorescent dyes. Following 1 h of incubation, the anionic dendrimer expanded
in the cytoplasm of the Kupffer cells, while it was retained in the plasma membrane of the hepatocytes. The uptake of the cationic derivative
by the hepatocytes was much more extensive compared to the anionic one.
Figure 2: In vivo biodistribution of liposomes labeled with 99m-
Technetium. Single photon emission computed tomography com-
binedX-ray computed tomography (SPECT-CT) datawere recorded
after 1.5 hours of the administration of labeled liposomes. The
distribution reflects that of non-PEGylated liposomes and shows
high uptake by the liver.
molecules) possible with wide variety of different chemical
characteristics. The first approved drug of this kind was the
liposomal doxorubicin (Doxil/Caelyx), which was followed
by many other liposomal products and currently hundreds
of such drugs are under clinical trials [40]. The major
breakthrough in the biomedical application of vesicles was
the development of sterically stabilized liposomes (SSLs:
Figure 3) that have longer half-life in the circulation than
conventional phospholipid liposomes.The former is achieved
by coating the surface of vesicles by lipopolymers such as
polyethylene glycol (PEG). Due to the important role of the
PEG layer of SSLs, the detailed characterization is required
for development of new liposomal products [27, 28, 38, 41].
The PEG surface, however, induces a pseudoallergic toxic
effect [42] or tolerance-like innate immunity and spleen
injury [18]; therefore the replacement of this polymer by
other biocompatible macromolecules is intensively studied.
Numerous studies are concerned about the more specific and
more efficient delivery of therapeutics by applying specific
combinations of biocompatible and biodegradable NMs ([33]
and reference cited). For recent examples we may conjecture
more efficient transfection of nucleic acid-based therapeutics
based on the modification of chitosan combined g-stearic
acid micelles by cis-aconitate [34] or more effective targeted
delivery of osthole by N-succinyl-chitosan nanoparticles
coupled with low-density lipoprotein [22].
Widespread natural polysaccharide chitosan has received
increasing medical attention via encapsulating anticancer
drugs such as 5-fluorouracil [43], doxorubicin [44, 45],
paclitaxel [46], cisplatin and camptothecin [47], and osthole
[22]. Abundant availability, unique mucoadhesivity, inherent
pharmacological properties, and other beneficial biological
properties such as biocompatibility, biodegradability, low tox-
icity, and low immunogenicity make chitosan an exception-
ally attractive NM for targeting therapeutics [48, 49]. Chi-
tosan, a linear amino polysaccharide composed of randomly
distributed 𝛽-(1→ 4) linked D-glucosamine and N-acetyl-D-
glucosamine units, can be obtained by the deacetylation of
chitin isolated from the exoskeleton of crustaceans such as
crab and shrimp [49]. The physicochemical and biological
properties of chitosan are greatly influenced by its molecular
weight and degree of deacetylation. Due to its reactive NH
2
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Figure 3: 2D SAXS pattern of polyethylene glycol (PEG) layered sterically stabilized liposomes (a), and the radially averaged 1D scattering
curve as the function of the scattering variable 𝑞(nm−1) (b).The value of 𝑞 is proportional to the scattering angle.The latter carries information
about the structure of the phospholipid bilayer and the thickness of the PEG layer on the surface of the liposomes.
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Physical, physicochemical
and chemical
examination of NMs (e.g.,
PLGA, liposomes, dendrimers, and
chitosan):
∙ NMR
∙ SAXS
∙ TEM, FF-TEM
∙ Dynamic light scattering
∙ Molecular dynamics calculations
∙ Etc.
∙ Organ level (e.g., PET, SPECT-CT, and 
near-infrared in vivo fluorescent
imaging)
∙ Cellular level (e.g., in vivo/in vitro
fluorescent imaging, synchrotron
radiation-based FTIR, and X-ray)
∙ Subcellular level (e.g., FF-
TEM, SFG, and in vitro
fluorescent imaging)
∙ Mitochondrial function (oxidative stress)
∙ Brain cell function (neurons,
astrocytes, microglia)
∙ Liver function (hepatocytes,
Kupffer cells)
∙ Blood serum interactions
∙ Human multidrug trans-
porters (chemodefense)
∙ Liposomes (membrane
interactions)
∙ Comparing standard
and modified NMs
∙ Validation of nanotoxicity
prediction by evaluation of
modified NMs
∙ Release of a less toxic modified
NM for further processing
Figure 4: Suggested work-scheme for safety assessment of nanomaterials.
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groups, facile chemical modifications [50] make it possible
to prepare a wide variety of chitosan-based NMs providing
more appropriate targeted drug delivery.These NMs include,
for example, cross-linked chitosan, chitosan-polyelectrolyte
complex, self-assembled chitosan, or PEGylated chitosan
[51]. Modifications made to chitosan, however, could make
it more or less toxic and any residual reactants will affect
toxicological properties of the product. Therefore, care must
be taken to ensure that the modified chitosan-based NMs
will be free from contaminants such as proteins, metals, or
the coupling agents which could potentially increase toxicity
[52]. In vitro toxicity of chitosan was found to be related to
the molecular weight and concentration at high degree of
deacetylation, while at lower degree of deacetylation toxicity
is less pronounced and less related to the molecular weight
[53, 54]. Acute toxicity tests predicted no “significant toxic
effects” in mice, as well as no eye or skin irritation in rabbits
and guinea pigs, respectively. In addition, chitosan was not
found pyrogenic [55]. One of the least studied characteristic
of chitosan is its biodistribution, especially by administration
methods other than intravenous. The biodistribution is both
molecular weight- and formulation-dependent presenting
relatively long circulation times [52]. The biodistribution is
critically dependent on route of administration, dosage form,
and chitosan characteristics. In the case of a nanoparticulate
formulation, the kinetics and biodistribution will initially
be controlled by the size and charge of the chitosan-based
NM and not by chitosan traits. However, after NM particle
decomposition to chitosan and free drug inside the cells
or target tissue, free chitosan will distribute in the body
and eliminate accordingly. Labeling techniques using amine-
reactive fluorescent indicators (FITC, 9-anthraldehyde) or
radionuclide-labeled chitosan derivatives were found to be
reliable to follow kinetics of chitosan biodistribution [56, 57].
5. Listening to Dendrimers
NM polymers forming branching dendrimeric structure give
opportunities for the targeted delivery of therapeutics that
can alleviate various pathways implicated in the damage
of the brain ([11, 19, 31, 35] and references cited). Report-
edly, dendrimeric NMs give a chance for nanoformulation,
enabling brain restoration and facilitating cellular growth
under specific conditions such as cerebral palsy [31] or
ischemia/stroke [58]. However, clinical use of dendrimers
may be seriously compromised by PAMAM dendrimer-
induced mitochondrial dysfunctioning or autophagy, par-
tially mediated by intracellular ROS generation [19]. Lysoso-
mal dysfunctioning may also be anticipated [19, 59]. Param-
eters indicating early appearance of nanotoxicity followed by
cell death were found to be irreversible depolarization of neu-
ronal and mitochondrial membranes, astroglia activation,
and changing Ca2+ homeostasis [12]. Size, charge, and other
surface characteristics of dendrimers were clearly identified
as being critical for nanotoxicity predictions of dendrimers
(Figure 1; [11, 35, 36]). Conjugation of surface amino groups
of G5-NH
2
by 𝛽-D-glucopyranose units reduced functional
neurotoxicity that may hold significant promise for biotech-
nology and medical applications.
Detection of early changes in membrane permeability of
living neuronal cells identified giant membrane depolariza-
tion and subsequent cell death evoked by the protein-like
PAMAM G5-NH
2
dendrimer. Structural changes observed
by applying SFG, SAXS, transmission electron microscopy
(TEM) techniques, and molecular dynamics calculations
indicate interactions of G5-NH
2
with model membranes.
These interactions suggest the hypothesis that G5-NH
2
inserts in the plasma membrane forming specific Na+ ion-
permeable channels. In this way, we were able to attribute
specific and irreversible action of PAMAM dendrimer G5-
NH
2
to the formation of Na+ ion-permeable channels in
neuronal plasma membrane [13]. The bright side of the
facet may be some potential antibacterial propensity against
resistant strains possibly ascribed to PAMAM G2-NH
2
[20]
or G5-NH
2
dendrimer embedding into the bacterial cell
envelope (wall and/or plasma membrane). The Na+ channel-
forming tendency together with the observed obstructive
effects of PAMAM dendrimer G5-NH
2
on E. coli prolifera-
tion but not on erythrocytes [13] together with the known
antibacterial effect of gramicidin and related peptides calls
the ion channel-forming predisposition into a common
antiresistant mechanism of action, constituting the future for
a postantibacterial era. Findings that resistance of Klebsiella
pneumoniae and Escherichia coli strains towards extended-
spectrum beta-lactams was partly due to the loss of the porin
OmpK35 [60] may be conjectured.
6. Unique Biodistribution of NMs and
Pertaining Model Systems to Study
Nanotoxicity
NMs have unique biodistribution due to their highly differ-
ent pharmacokinetic properties as compared to small drug
molecules [61–64]. In predicting toxicity of drug molecules,
well-tested and validated assays are available. Uncritical
applications of these assays to toxicity evaluation of NMs,
however, require caution due to distinguishable pharma-
cokinetics of NMs. NMs may possibly be transported in
the body via the lymphatic system that complicates their
pharmacokinetic analysis based on blood sampling and also
exposes lymphoid tissue to higher concentrations thanwould
be seen secondary to distribution fromblood [38]. It has been
shown that, for NMs, decline in blood concentrations can be
related to the compound movement into tissues where fur-
ther excretion does not occur. This way NMs can be trapped
in reticuloendothelial system, bound to tissue proteins, or
can showpostdistributional aggregation. In these cases, blood
half-life may paradoxically be relatively short despite the
prolonged body persistence [65]. For example, a complete
lack of excretion of quantum dots has been demonstrated
28 days after their application [66]. Although plasma half-
life was short, there was a continued redistribution from
body sites to liver and kidney throughout 28 days [66].
For many NMs, liver has been proved to be one of the
final deposits amongst organ tissues. However, in contrast
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to small organic molecules, NMs accumulated mostly in the
Kupffer cells but not in the hepatocytes ([67] and Figure 2).
It has also been shown that with a decrease in the blood
concentrations of someNMs, liver and spleen concentrations
significantly increased.These findings suggest that theseNMs
were opsonized and cleared from the blood by circulating
phagocytes and tissue macrophages such as hepatic Kupffer
cells, neural microglia, and spleen macrophages [21, 61,
64, 68, 69]. It is to note that nanoformulation of drug
molecules or using NMs for their targeting might enhance
drug permeation across the blood-brain barrier changing
their biodistribution [70]. In a physiological environment
NMs are immediately coated by a dynamical layer of proteins,
leading to a protein “corona” [71]. Protein binding is one of the
key elements affecting biodistribution, biocompatibility, and
therapeutic efficacy of the NMs [72, 73]. These interactions
may alter protein conformations, as well. The plasma protein
adsorption on NMs, influencing its uptake into cells from
the bloodstream, strongly depends on the particle size and
physicochemical properties of the NM. Interaction of various
NMs with the most abundant human serum albumin (HSA)
has been investigated [74, 75]. Systematic studies on the
interaction of the main drug binding components of human
plasma HSA or alpha
1
-acid glycoprotein (AGP) with NMs
may possibly influence not only the free concentrations of
exogenous and endogenous ligands [76, 77], however, the
biodistribution of NMs as well.
6.1. Seven Layers of Nanotoxicity Understanding. In
selecting the most appropriate parameters for the
assessment of potential toxic effects of NMs, we
suggest to apply existing safety assessment protocols
(http://ncl.cancer.gov/assay cascade.asp) as well as exploring
novel pertaining functional model systems. Understanding
nanotoxicity of NMs requires ramifying series of knowledge,
including preparation, biodistribution, metabolism and
pharmacokinetics, toxicological profile, and immunological
consequences [7]. Further nanotoxicity research underlying
biomedical applications could focus on:
(1) the rigorous examination of the physical, physico-
chemical, and chemical nanoscale characteristics fea-
turing a selected set of known “nontoxic” and “toxic”
standard NMs in order to establish “nanotraits” of
NMs under consideration (Figure 4, Block 1): beside
their pharmaceutical applications, liposomes can also
be used as in vitro model systems to predict the
toxic effects of other NMs. The complex structural,
morphological, and thermodynamic studies of both
uni- and multilamellar vesicles in the presence of
NMs (dendrimers, quantum dots, etc.) could be
able to conclude lipid bilayer interferences projecting
possible NM mechanisms of action on the cellular
plasma membrane;
(2) the establishment and characterization of biological
models of increasing complexity (cellular, tissue, and
organism levels), including human cell-based nonan-
imal in vitromodels such as induced pluripotent stem
cells in order to establish biodistribution (Figure 4,
Block 2);
(3) the disclosure of the NM trait-related biological
properties and mechanisms of NM toxicity by using
and further developingmodel systems and comparing
“nontoxic” and “toxic” standardNMs (Figure 4, Block
3): researchers may want to further (i) monitoring
mitochondrial (dys)functions [15, 19, 78]; (ii) assaying
special organs with limited regeneration capacity, for
example, acute/cultured brain tissue slices to assess
short- and medium-term NM effects, asking for
proper functioning of neurons [11, 15, 35] and glia
[12, 15] or the blood-brain barrier (BBB: [79, 80]);
(iii) following activation/inactivation of microglia
subtypes, providing information on potential neu-
roinflammatory effects of NMs [81, 82] completed by
(iv) assaying hepatotoxic effect of NMs by measuring
basic hepatic functions, such as transport of bile salts
and bilirubin through the basolateral and canalic-
ular membranes via the SLCOs, SLC10A1, ABCC3,
ABCB11, and ABCC2 transporters, respectively, in
sandwich coculture of hepatocytes [83–85] with or
without of Kupffer cell subtypes [21, 62, 86], (see
also Figures 1 and 2); (v) investigations of the altered
bile acid regulation of the function of the human
multidrug transporter expressed in model systems
by the presence of NMs [87, 88]; (vi) investigating
the interactions between NMs and blood serum or
plasma [89, 90];
(4) the validation of nanotoxicity prediction through
evaluation of NMs modified according to the new
knowledge and understanding gained through in
vivo studies (Figure 4, Block 4): after more than 250
different nanoparticle analyses, researchers of the
Nanotechnology Characterization Laboratory at the
National Cancer Institute have addressed issues of
concerns, comprising sterility and endotoxin con-
tamination, proper specification and purity, biocom-
patibility, uniformity of NM batches, and stability
monitoring; [7].
(5) the iterative establishment of standard work-scheme
for the safety assessment of NMs (Figure 4, Blocks 1–
4): the multidisciplinal approach involving physical,
physicochemical, and chemical characterization of
NMs, followed by determination of biodistribution
on multiple levels of complexity and assessing the
toxicity of the well-described NMs on functional
nanotoxicity platforms is expected to generate deeper
understanding of the interactions between NMs and
biological environments. The gained knowledge may
eventually lead to the release of less toxic mod-
ifications of NMs providing “proof-of-concept” of
prediction;
(6) the establishment and running of publicly available
information sources addressing nanotoxicity that
provide in-depth experimental data for researchers
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and industrial players: it is also advisable to use this
channel to inform the lay audience.
7. Future Outlook
Potential environmental toxicity of NMs may have a major
impact on their further development and applications. To
focus on the discovery of toxic effects of widely used NMs
requires multidisciplinary research. NMs—applied in elec-
tronics, solar energy capturing, or chemistry to areas of
biotechnology andmedicine—are supposed to be thoroughly
characterized first. Next, examination of NM distribution
in live tissue and the blood should be combined with the
study of immediate organ-level effects especially regarding
the function of the brain and the liver. We suggest a range
of biochemical, cellular, and immunological processes to
be explored in order to provide information on the early
effects of NMs on some basic functions and chemical defense
mechanisms. Understanding of long-term nanotoxicity is
also supposed to be achieved by studying effects of NMs
on the development, cell differentiation, metabolism, and
genetic stability.
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